Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review

Abstract

Epidermolysis bullosa (EB) is a group of rare mucocutaneous fragility disorders often presenting in infancy and early childhood with painful blistering of the skin and mucous membranes. The severity of EB blister burden varies by disease subtype. Studies have shown that patients with generalized severe epidermolysis bullosa simplex (EBS), a variant characterized by extreme fragility, develop blisters in the setting of overproduced, mutated K14 protein, a component of the intermediate filament integral in keratinocyte stability, and constitutive activation of interleukin (IL)-1 , a pro-inflammatory cytokine that promotes the hyperproliferation of keratinocytes. Diacerein, a rhein prodrug and anthraquinone, has been shown to reduce expression of K14 and inhibit IL-1 converting enzyme. In clinical trials, topical 1% diacerein was shown to be an effective and safe, non-invasive treatment for patients suffering from EBS. This review examines the clinical trials of topical diacerein and its role in EBS. Diacerein ointment was granted US FDA Rare Pediatric Disease designation in May 2018 and Fast Track development designation in August 2018.

• Authors: Allison L Limmer, Crystal E Nwannunu, Radhika Shah, Kendall Coleman, Ravi R Patel, Uyen Ngoc Mui, Stephen K Tyring
• Journal: Skin therapy letter (Skin Therapy Lett) Vol. 24 Issue 3 Pg. 7-9 (05 2019) ISSN: 1201-5989 [Print] Canada
• PMID: 31095348 (Publication Type: Journal Article, Review)

Chemical References

• Anthraquinones
• Anti-Inflammatory Agents
• diacerein

Topics

• Administration, Cutaneous
• Anthraquinones (administration & dosage, therapeutic use)
• Anti-Inflammatory Agents (administration & dosage, therapeutic use)
• Epidermolysis Bullosa Simplex (drug therapy)
• Humans